Blacksburg, VA (PRWEB) February 14, 2012
Techulon Inc., developer of low-toxicity DNA and RNA delivery technology, announced today that its platform demonstrated lower cytotoxicity than PEI when used to transfect human embryonic kidney (HEK293) and murine macrophage (RAW264.7) cells in a study published in the peer reviewed journal Pharmaceutical Development and Technology.
The paper, entitled “Poly(galactaramidoamine) is an efficient cationic polymeric non-viral vector with low cytotoxicity for transfecting human embryonic kidney (HEK293) ad murine macrophage (RAW264.7) cells,” was conducted by Drs. Wongrakpanich, Joshi and Salem of the Department of Pharmaceutical Sciences and Experimental Therapeutics in the College of Pharmacy at the University of Iowa in Iowa City, Iowa.
“The availability of a robust, non-toxic delivery platform is key to advancing the state of therapeutics. We are pleased to see Techulon’s work in cationic polymers leading to more efficient and safe delivery capabilities,” said Dr. Aliasger Salem.
Glycofect™, a biodegradable DNA delivery platform, was introduced in mid-2010 and has been used by over 300 collaborators in 20 countries. Recent successes include publication of results where Glycofect was effective for in vivo delivery of inhibitors to prevent damage to heart tissue.
Techulon holds exclusive licenses for the PGAA polymers used in the study. The company is focused on developing advanced delivery technologies for therapeutic applications. Techulon’s platform is designed for use by partner companies in collaboration to engineer safer, more effective cell therapies. The company provides access to the platform through licensing and collaboration arrangements.
Techulon, Inc. is a life sciences company headquartered in Blacksburg, VA, with a core capability in novel biodegradable and low toxicity DNA and RNA delivery technologies for cell-based research and therapeutics. For more information please visit the company website at http://www.techulon.com.